Which medications can cause muscle weakness?

Medications That Cause Muscle Weakness

Statins are the most common medication class causing muscle weakness, ranging from mild myalgias to severe rhabdomyolysis, with risk substantially increased when combined with fibrates, colchicine, cyclosporine, or in patients with renal insufficiency. 1

High-Risk Medication Classes

Statins (HMG-CoA Reductase Inhibitors)

• All statins can cause myopathy, presenting as muscle ache or weakness without CK elevation (myalgia), muscle symptoms with increased CK (myositis), or severe muscle symptoms with marked CK elevation >10× ULN plus creatinine elevation (rhabdomyolysis). 1
• Cerivastatin (withdrawn from market) had 16-80 times higher fatal rhabdomyolysis rates compared to other statins. 1
• Statin-induced muscle weakness occurs in approximately 5-10% of patients in routine clinical practice, though clinical trials report lower rates around 5% similar to placebo. 1, 2
• Immune-mediated necrotizing myopathy (IMNM) is a rare but severe statin complication characterized by persistent proximal muscle weakness and elevated CK (mean ~6,800 U/L) that continues even after statin discontinuation and requires immunosuppressive therapy. 1, 2

Corticosteroids

• Acute myopathy with high-dose corticosteroids is generalized, may involve ocular and respiratory muscles, and can result in quadriparesis with CK elevation. 3
• This occurs most often in patients with neuromuscular transmission disorders (e.g., myasthenia gravis) or those receiving concomitant neuromuscular blocking drugs. 3
• Clinical improvement after stopping corticosteroids may require weeks to years. 3

Fluoroquinolone Antibiotics

• Fluoroquinolones cause muscle weakness, particularly in patients with myasthenia gravis, and should be avoided in this population. 4
• Muscle syndromes range from mild myalgias (possibly the most common adverse effect) to life-threatening rhabdomyolysis, typically manifesting within 1 week of initiation. 1
• Symptoms consist of diffuse muscle pain with or without weakness, with possible predilection for proximal muscle groups, and usually resolve within 1-4 weeks after discontinuation (though persistence up to 6 months has been reported). 1

Colchicine

• Colchicine causes myopathy with associated neuropathy, classified as a painful neuromyopathy. 5
• When combined with statins, colchicine causes rapid onset of muscle weakness (within 3 weeks), particularly in patients with renal insufficiency. 6
• This combination produces profound lower extremity weakness with inability to stand or walk, elevated muscle enzymes, and EMG findings consistent with myopathy. 6

Antimalarial Drugs

• Chloroquine and hydroxychloroquine cause vacuolar myopathy with associated neuropathy. 5
• These are classified as painless myopathies with neuropathy. 5

Critical Drug Combinations That Increase Myopathy Risk

The following combinations dramatically increase muscle weakness risk and require vigorous surveillance:

• Statins + fibrates (especially gemfibrozil): More than 60% of fatal cerivastatin cases involved gemfibrozil co-administration. 1
• Statins + colchicine: Causes rapid-onset severe weakness within weeks, especially with renal insufficiency. 6
• Statins + cyclosporine: Substantially increases myopathy risk through drug interactions. 5
• Statins + macrolide antibiotics (erythromycin, clarithromycin): Inhibit CYP3A4 metabolism, increasing statin levels. 1
• Statins + azole antifungals (ketoconazole, itraconazole): Can decrease statin metabolism by up to 60%. 1
• Fluoroquinolones + corticosteroids: Post-marketing surveillance indicates increased tendon rupture risk, especially in elderly patients. 3

Additional Medications Causing Myopathy

• D-penicillamine: Causes both myasthenic syndromes and polymyositis. 5
• Zidovudine: Causes mitochondrial myopathy and polymyositis. 5
• Amiodarone: Causes vacuolar myopathy. 5
• Vincristine: Causes necrotizing myopathy. 5
• Cimetidine: Associated with polymyositis. 5
• Drugs causing hypokalemia: Can induce vacuolar myopathy. 5

Risk Factors That Increase Medication-Induced Muscle Weakness

• Renal impairment: Dramatically increases myopathy risk, particularly with statins and colchicine combinations. 2, 6
• Hypothyroidism: Predisposes to myopathy and exacerbates statin-related muscle injury; check TSH in any patient on statins with muscle symptoms. 2, 7
• Advanced age (>60 years): Increases risk, particularly with fluoroquinolones and statins. 4
• Female gender: Increases statin-induced myopathy risk. 2
• Asian descent: May have increased statin sensitivity. 8
• Vitamin D deficiency: Increases muscle symptom risk with statins. 2
• Pre-existing muscle disease or myasthenia gravis: Substantially increases risk with corticosteroids and fluoroquinolones. 3, 4

Clinical Presentation Patterns

Painless myopathies without neuropathy:

• Corticosteroids (chronic use causes proximal weakness without pain) 5

Painless myopathies with neuropathy:

• Colchicine, chloroquine, hydroxychloroquine 5

Painful myopathies without neuropathy:

• Statins, clofibrate, cyclosporin 5
• D-penicillamine, cimetidine, zidovudine (polymyositis pattern) 5

Myasthenic syndromes:

• D-penicillamine, certain antibiotics, beta-blockers 5

Monitoring and Prevention

• Obtain baseline CK before starting statins and compare to levels when symptoms develop. 2
• Check TSH promptly in any patient on statins with elevated CK or muscle symptoms. 2, 7
• Use the lowest effective statin dose required to achieve therapeutic goals. 9
• Avoid polytherapy with drugs known to increase systemic statin exposure (CYP3A4 inhibitors, fibrates). 9
• Monitor patients receiving statin-fibrate combinations carefully, though this combination is now considered an option with careful monitoring per ATP III guidelines. 1
• Discontinue statins immediately if CK >10× ULN or if muscle symptoms develop with any CK elevation. 2, 7

Important Caveats

• Muscle complaints occur in ~5% of both statin and placebo groups in controlled trials, suggesting many complaints may be non-specific rather than drug-related. 1
• However, temporal association with drug initiation often implicates the medication despite similar placebo rates. 1
• Fatal rhabdomyolysis with statins is extremely rare (<1 death per million prescriptions for all statins except cerivastatin). 1
• Rechallenge with the same drug after myopathy is not advisable due to risk of serious relapse. 5
• The exact mechanisms by which most drugs cause myopathies remain unknown, though some involve metabolic changes while others may be immune-mediated. 5